# Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis

> **NCT07689942** · — · AVAILABLE · sponsor: **Biodexa Pharmaceuticals**

## Conditions studied

- Familial Adenomatous Polyposis (FAP)

## Interventions

- **DRUG:** eRapa (encapsulated rapamycin)

## Key facts

- **NCT ID:** NCT07689942
- **Lead sponsor:** Biodexa Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689942, "Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07689942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*